Status Epilepticus - Pipeline Review, H2 2015

Published: Jul, 2015 | Pages: 52 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Status Epilepticus - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Status Epilepticus - Pipeline Review, H2 2015', provides an overview of the Status Epilepticus's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Status Epilepticus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Status Epilepticus and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Status Epilepticus
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Status Epilepticus and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Status Epilepticus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Status Epilepticus pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Status Epilepticus
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Status Epilepticus pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Status Epilepticus Overview 6
Therapeutics Development 7
Pipeline Products for Status Epilepticus - Overview 7
Pipeline Products for Status Epilepticus - Comparative Analysis 8
Status Epilepticus - Therapeutics under Development by Companies 9
Status Epilepticus - Therapeutics under Investigation by Universities/Institutes 10
Status Epilepticus - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Status Epilepticus - Products under Development by Companies 13
Status Epilepticus - Products under Investigation by Universities/Institutes 14
Status Epilepticus - Companies Involved in Therapeutics Development 15
Ligand Pharmaceuticals, Inc. 15
Sage Therapeutics 16
Status Epilepticus - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 25
ADD-405008 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
AMPX-0079 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
fosphenytoin sodium - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
SAGE-217 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
SAGE-547 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
SAGE-689 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
TG-4155 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Status Epilepticus - Recent Pipeline Updates 35
Status Epilepticus - Dormant Projects 39
Status Epilepticus - Product Development Milestones 40
Featured News & Press Releases 40
Jun 09, 2015: SAGE Therapeutics Announces Positive Top-Line Data in Exploratory Trial of SAGE-547 in Postpartum Depression 40
May 14, 2015: SAGE Therapeutics Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in Super-Refractory Status Epilepticus 41
Apr 22, 2015: Ligand Earns Milestone from SAGE Therapeutics for SAGE-547 43
Apr 20, 2015: SAGE Therapeutics Announces First Patient Treated Under Phase 3 Expanded Access Protocol to Evaluate SAGE-547 in Patients with Super-Refractory Status Epilepticus 43
Apr 09, 2015: SAGE Therapeutics presents Phase 1/2 clinical trial data on SAGE-547 at Upcoming Scientific Conferences 44
Apr 09, 2015: SAGE Therapeutics presents preclinical data on SAGE-689 at Upcoming Scientific Conferences 45
Apr 02, 2015: SAGE Therapeutics Announces Positive End-of-Phase 2 Meeting With FDA and Planned Initiation of SAGE-547 Global Phase 3 Trial in Mid-2015 45
Jan 09, 2015: SAGE Therapeutics Reports Updated Data from Ongoing Clinical Trial and Emergency Use Program of SAGE-547 in Patients with Super-Refractory Status Epilepticus 47
Nov 10, 2014: SAGE Therapeutics Reports Positive Top-Line Phase 2 Data of SAGE-547 in Patients With Super-Refractory Status Epilepticus 48
Nov 03, 2014: First Evaluation of SAGE-547 to Treat Super-Refractory Status Epilepticus in Children Published in Annals of Neurology 49
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 51
Disclaimer 52

List of Tables

Number of Products under Development for Status Epilepticus, H2 2015 7
Number of Products under Development for Status Epilepticus - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Late Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Products under Investigation by Universities/Institutes, H2 2015 14
Status Epilepticus - Pipeline by Ligand Pharmaceuticals, Inc., H2 2015 15
Status Epilepticus - Pipeline by Sage Therapeutics, H2 2015 16
Assessment by Monotherapy Products, H2 2015 17
Number of Products by Stage and Target, H2 2015 19
Number of Products by Stage and Mechanism of Action, H2 2015 21
Number of Products by Stage and Route of Administration, H2 2015 23
Number of Products by Stage and Molecule Type, H2 2015 24
Status Epilepticus Therapeutics - Recent Pipeline Updates, H2 2015 35
Status Epilepticus - Dormant Projects, H2 2015 39